Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC and Radiation for Low-Risk Rhabdomyosarcoma
NCT00075582Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Sep 2004
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
Phase 3, open-label trial of vincristine sulfate liposome injection, actinomycin D and cyclophosphamide (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Failure-Free Survival at 5 years. Started Sep 2004; status: completed.
02
Drugs
vincristine sulfate liposome injectionactinomycin Dcyclophosphamide
Beyond the preview
Go deeper on NCT00075582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075582.